Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Peritoneal Carcinomatosis Clinical Trial

— PASIREOCHIP  

Official title:

Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04826432
• Other study ID #: 2019-002507-18
• Secondary ID: 2019/2955
• Status: Terminated
• Phase: Phase 2
• Start date: September 3, 2020
• Est. completion date: February 7, 2024

Study information

• Verified date: February 2024
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: February 7, 2024
• Est. primary completion date: February 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or female patients aged between 18 years and 75 years included

• ECOG (Eastern Cooperative Oncology Group) Performance Status = 2

• Primary (pseudomyxoma peritonei, peritoneal mesothelioma) or Secondary (colorectal or ovarian) peritoneal malignancies

• Curative intent resection obtained by a complete resection according to the Completeness of Cytoreduction score (CC) (CC 0-1) followed by HIPEC Different intraperitoneal drug administration modalities such as neoadjuvant systemic plus simultaneous intraperitoneal and intravenous chemotherapy (NIPS) or pressurized intra-peritoneal aerosol chemotherapy (PIPAC) does not represent exclusion criteria.

• Absence of extra-peritoneal metastatic disease or limited hepatic or lung metastases easily amenable to curative-intent resection or ablation

• Intraoperative Peritoneal Cancer Index (PCI score) = 10

• Visceral resection with at least one digestive anastomosis with or without loop ileostomy or pancreatic or biliary resection.

• Negative serum pregnancy test for women of childbearing potential within 7 days prior to therapy

• Sexually active women of childbearing potential must agree to use a highly effective method of contraception or to abstain from sexual activity during the study and for 3 months after the last study treatment administration. Sexually active males patients must agree to use condom or to abstain from sexual activity during the study and for 3 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception during the same period.

• Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.

• Patients must be affiliated to a social security system or beneficiary of the same

Exclusion Criteria:

• Macroscopically incomplete surgical resection (CC 2)

• Standard contraindications to pasireotide:

1. patients with uncontrolled diabetes mellitus or a fasting plasma glucose > 250mg/dl (14 mMol/L)

2. patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia including a corrected QT (QTc) interval longer than 450 msec, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment

3. patients with liver disease such as severe hepatic impairment (Child Pugh C), chronic active hepatitis or chronic persistent hepatitis with abnormal coagulation (INR>1.5).

4. patients with the presence of active or suspected acute or chronic uncontrolled infection

5. hypersensitivity to somatostatin analogues or any component of pasireotide formulations

6. patients with uncontrolled hypothyroidism

• Patients participating or who have participated to another study evaluating the effect of a new drug other than pasireotide within 1 month prior to dosing

• Patient who have already participated to this study (a patient can only be included once in the study)

• Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study.

• Women who are pregnant or likely to be so, or who are breastfeeding

• Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent

Related Conditions & MeSH terms

• Carcinoma
• Peritoneal Carcinomatosis
• Peritoneal Neoplasms

Intervention

Drug:
• Pasireotide 0.9 MG/ML
0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours

Other:
• Saline water
0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours

Locations

Country	Name	City	State
France	Gustave Roussy	Villejuif

Sponsors (1)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	postoperative digestive leakage	The rate of clinically relevant (NCI CTCAE v5 = grade 3) postoperative digestive leakage at 97 days	97 days